Navigation Links
Sinapis Pharma Completes Phase I Trial
Date:7/11/2011

JACKSONVILLE, Fla., July 11, 2011 /PRNewswire/ -- Sinapis Pharma, Inc. is pleased to announce that it has completed its first clinical trial in the development of its lead drug for the treatment of stroke and traumatic brain injury.  The Phase I trial entitled " A Phase 1, Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single Dose, Crossover Study to Evaluate the Safety and Pharmacokinetics of Oral and Intravenous Administration of Methamphetamine Hydrochloride in Healthy Volunteers" was conducted at Prism Research in St. Paul, MN.

This was a single-center, open-label, randomized, two-period, two-treatment, two-sequence, single dose, crossover study of the safety and pharmacokinetics of oral and IV administration of methamphetamine HCl in six healthy volunteers.  Subjects were randomized 1:1 to receive a single oral dose of methamphetamine HCl (5 mg Desoxyn® tablet) or a single IV dose of methamphetamine HCl (5 mL of 0.5 mg/mL methamphetamine HCl injection infused over one hour for a total dose of 2.5 mg), and then crossed over to the other treatment (i.e., IV or oral dose, respectively) after a 10 day washout period.  Subjects received a single dose of study drug on Day 1 of each of the two treatment periods.

The trial successfully demonstrated the safety of an IV infusion of Methamphetamine and produced the IV infusion pharmacokinetics needed to initiate Phase IIa clinical studies in stroke patients.

Sinapis plans to initiate its Phase IIa trial in stroke patients before year end.

Dr Donald Picker, Sinapis CEO, said  "We are very pleased  and excited to complete the next step in the development of this drug for stroke and traumatic brain injury patients. We are eager to begin the proof of principle trials in these very important indications where there are currently no effective treatments."

Sinapis Pharma, Inc. (www.sinapispharma.com) is an early stage biotechnology company whose lead compound methamphetamine, as a low-dose intravenous infusion, has shown remarkable pre-clinical efficacy in stroke and brain injury models.


'/>"/>
SOURCE Sinapis Pharma, Inc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
2. SCOLR Pharma, Inc. Announces Final Closing of Private Placement
3. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
4. Dr. Joel Posener Joins PharmaNet as Executive Medical Director, Neuroscience
5. PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation
6. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
7. Genesis Biopharma Conference Call and Webcast Reminder
8. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
9. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
10. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
11. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit ... 7th and 8th June 2018 in San Francisco, CA. The Summit brings together current ... several distinguished CEOs, board directors and government officials from around the world to address ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):